Priority 21 from the Kidney Transplant PSP
| UNCERTAINTY: How do we prevent the original cause of kidney failure returning (for example glomerulonephritis) following kidney transplant? | |
|---|---|
| Overall ranking | Priority questions agreed on but not put in ranked order |
| JLA question ID | 0037/21 |
| Explanatory note | Not available for this PSP |
| Evidence |
Ongoing Randomised Controlled Trial: Burke G. Rituximab to prevent recurrence of proteinuria. NCT01164098 |
| Health Research Classification System category | Renal and Urogenital |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples |
Having suffered prior to transplant from glomerulnephritis,is there any risk that the transplanted kidney could be affected by this condition? Is rituximab and/or plasma exchange effective in the management of recurrent FSGS post-transplant? How can we prevent or treat the recurrence of IgA nephropathy following renal transplantation? |
| Comparison | Drug |
| Submitted by |
Patient x 1 Clinicians x 2 |
| Outcomes to be measured | Recurrent FSGS |
| PSP information | |
|---|---|
| PSP unique ID | 0037 |
| PSP name | Kidney Transplant |
| Total number of uncertainties identified by this PSP. | 90 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 3 February 2016 |